Arbutus Biopharma EV/EBIT ABUS

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2016.

Today, Oct 23, 2026: 4.9×
10-year median: 2.6×
Against its 10-year history: 78th; percentile: 0 is its lowest day, 100 its highest
10-year range: 0.1× to 6.3×
Peer median: 7.6×

Arbutus Biopharma's EV/EBIT is 4.9× as of Oct 23, 2026.

That is above its ten-year median of 2.6×, higher than on 78% of days in the last ten years.

Over that time it ranged from 0.1× in Nov 2016 to 6.3× in Aug 2026.

The median for 10 large drugmakers of a similar size is 7.6×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	4.9×	4.7×	6.3×
2025	n/m a value too high to mean anything
2024	n/m a value too high to mean anything
2023	n/m a value too high to mean anything
2022	n/m a value too high to mean anything
2021	n/m a value too high to mean anything
2020	n/m a value too high to mean anything
2019	n/m a value too high to mean anything
2018	2.9×	2.4×	2.9×
2017	2.4×	0.3×	4.0×
2016	0.6×	0.1×	1.1×

Against its peers

Companies in Drug Manufacturers - General nearest Arbutus Biopharma's size, closest first, today.

Company	EV/EBIT
ABUSArbutus Biopharma	4.9×
COLLCollegium Pharmaceutical	9.4×
AMPHAmphastar Pharmaceuticals	12.2×
CRMDCorMedix	2.3×
ZVRAZevra Therapeutics	2.9×
OMEROmeros	n/m
IRWDIronwood Pharmaceuticals	3.5×
PBYIPuma Biotechnology	15.6×
ARVNArvinas	n/m
PCRXPacira BioSciences	7.6×
ANABAnaptysbio	n/m
Peer median	7.6×

Where Arbutus Biopharma ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Arbutus Biopharma

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.